Radha Gopalan, a heart transplant cardiologist at Banner–University Medical Center Phoenix, was troubled by a particular kind of patient: someone sick enough to need a new heart, hospitalized and unable to go home before surgery, but too frail to survive the transplant and its grueling recovery, and therefore turned down. Existing prehabilitation programs, structured exercise, nutrition, and psychological support before major surgery, were built for outpatients well enough to be at home, which left the sickest, most frail, already-hospitalized candidates with no way to build the strength that would let them qualify. So Gopalan's team developed an in-patient exercise program for exactly those patients, and reported at the International Society for Heart and Lung Transplantation meeting in Toronto this spring that it helped a meaningful share of previously ineligible patients become eligible for transplant.
The work is a humane and clinically valuable advance, and it is also worth thinking about carefully, because it quietly changes what the word "eligible" means. The program reveals that frailty-based ineligibility is often not a fixed fact about a patient but a movable threshold, one that depends on what care is available to move the patient across it. That reframing is genuinely good news for a group of very sick people, and it also raises a hard question about a scarce resource that the enthusiasm should not skip past.
Eligibility as a threshold, not a trait
The phrase "too frail to qualify" sounds like a statement about the patient, an immutable property, the way a lab value or an anatomical fact would be. On closer inspection it is not. It is a statement about the patient relative to the pre-surgical optimization available to them. A candidate judged too weak to survive transplant surgery is being measured against the strength they can reach given the care on offer, and if that care expands, so does the strength they can reach, and the same patient can cross the line from ineligible to eligible without any change in who they fundamentally are.
That is precisely what Gopalan's program does. It does not change the patients so much as change the pathway, adding a rung, in-patient prehabilitation for the hospitalized and frail, that did not exist before. And by adding that rung, it reclassifies patients who were "ineligible" under the old pathway as eligible under the new one. So "ineligible" was never a property of the patient alone. It was a property of the patient together with the care pathway available to them, and when the pathway improved, the classification changed. Eligibility turns out to be something you can sometimes build a patient into, not just something you measure and find them lacking.
A system limit that had been read as a patient limit
The implication is quietly significant and worth stating plainly, because it concerns life and death. If some frail candidates were ineligible only because no program existed to reverse their frailty, then some patients were being denied transplants, and, for end-stage heart failure, denied a chance at survival, not because they could not have been made eligible, but because the means to make them eligible had not yet been built. Their disqualifying frailty was treatable. It simply was not being treated, because the pathway to treat it in a hospitalized, pre-transplant patient did not exist.
That means part of what frailty-based ineligibility was doing, without anyone intending it, was excluding people whose weakness was reversible but unaddressed, and recording that exclusion as though it were a fixed limit of the patient rather than a gap in the system. Gopalan's contribution is to expose the gap and fill it, which rescues patients who were on the wrong side of a line that reflected the state of care as much as the state of their bodies. Reframing a system limitation that had been mistaken for a patient limitation is the kind of advance that expands what is possible for people who had been quietly written off, and on its own terms it is straightforwardly good.
The scarcity that complicates the good news
There is a tension the reframing forces into view, and honesty requires facing it rather than letting the uplift obscure it. Donor hearts are profoundly scarce. Only roughly 3,000 heart transplants are performed in the United States in a typical year, far fewer than the number of people who need one, and the allocation of those hearts is governed by a rationing system that weighs medical urgency, waiting time, and geography precisely because demand so exceeds supply.
Against that backdrop, making more patients eligible does not create more hearts. It enlarges the pool of people competing for a fixed and inadequate supply. This does not make the program wrong, and it emphatically does not mean the newly eligible patients are less deserving, questions of desert are the wrong frame for a tragic scarcity that forces impossible choices regardless. But it does mean the innovation lands inside a zero-sum constraint, where every candidate who becomes eligible competes with others, some of whom will not receive a heart in time. Expanding eligibility is unambiguously good for the individual patient who gains a chance they did not have. Its effect on the system is more complicated, because it intensifies an allocation problem that was already agonizing, and the honest account holds both of those truths at once.
The question the eligibility rate cannot answer
That tension sharpens a specific and answerable question, and it is the one that should govern how the program is judged over time. Qualifying for a transplant is not the goal; it is a proxy for the real goal, which is benefiting from the transplant, surviving it and living well afterward. Eligibility is a surrogate for outcome, and a surrogate is only as good as its connection to the thing it stands for.
So the crucial question about in-patient prehabilitation is whether it improves the outcome or merely the surrogate. There are two possibilities, and they have very different implications. In the first, prehabilitation genuinely reverses the frailty, rebuilding real physiological reserve, so that a patient who becomes eligible is actually more robust, more able to survive surgery and recover, not just nominally past a threshold. In that case the program improves both eligibility and outcomes together, and it is correcting an unjust exclusion, giving a scarce heart to someone who will benefit as much as anyone. In the second possibility, prehabilitation nudges patients just past the eligibility metric without producing real physiological change, in which case it has moved the number without moving the reality, and a scarce heart goes to a patient who will not do as well. The difference between those two is the entire question of whether the program is expanding access fairly or gaming a threshold, and it cannot be answered by counting how many patients qualified. It can only be answered by following how the transplanted patients actually fare.
Grounds for optimism, and the proof still owed
The reasons to expect the better answer are real, and worth stating so the analysis does not read as mere skepticism. A great deal of the frailty in these hospitalized patients is deconditioning, the muscle loss and weakness that come from being acutely ill and immobile for long stretches, and deconditioning is among the more genuinely reversible forms of frailty, responsive to structured exercise, nutrition, and support. That physiology gives good reason to think in-patient prehabilitation produces real strength rather than a cosmetic bump across a line, which would make the newly eligible patients genuinely better candidates and not merely qualifying ones. The clinical logic is sound, and the early enthusiasm is not unfounded.
But sound logic is a reason to run the study, not a substitute for it, and the evidence still owed is longer-term post-transplant outcomes, survival, functional recovery, freedom from complications, for the patients the program makes eligible, compared against what happens without it. The results presented in Toronto are a genuine start, and reporting how many patients qualified is a reasonable first milestone. It is not the finish line, because qualifying is the input and thriving after transplant is the output, and only the output tells you whether the surrogate tracked the outcome. The responsible posture is to hold the optimism and the demand for proof together: this very likely does real good, and the way to know is to measure the thing that matters rather than the thing that is easy to count.
How to read it
The clearest way to understand Gopalan's program is that it reveals frailty-based ineligibility to be, in many cases, a movable threshold reflecting a gap in the care pathway rather than a fixed trait of the patient, and that it humanely closes that gap for people who had been excluded by it. That is a real advance, and for the individual patients it reaches, it can be the difference between a chance at life and none. It also lands inside the hard reality of organ scarcity, where enlarging the pool of eligible patients does not enlarge the supply of hearts, so the benefit to individuals coexists with a more complicated effect on a rationing system that was already forced to choose among people it cannot all save.
The measure that matters, and the one to watch as the work matures, is whether prehabilitation improves the outcome that eligibility is supposed to stand for, real post-transplant survival and function, rather than only the eligibility metric itself. The physiology of reversible deconditioning gives strong reason to expect that it does, which is what makes this promising rather than merely clever, but that expectation is a hypothesis the outcomes data must confirm. The deeper lesson reaches past cardiology: when a threshold sorts people into eligible and ineligible, it is always worth asking whether the line describes the people or the tools available to help them, because sometimes what looks like a limit of the patient is a limit of the care, and that is a limit that can be moved.
Primary sources
- STAT's interview with Radha Gopalan of Banner–University Medical Center Phoenix for the account of the in-patient exercise program, its origin in patients who never went home before transplant and could not otherwise improve their frailty, the distinction between cardiac rehabilitation and cardiac prehabilitation, the goal of helping frail patients qualify for transplantation, and the presentation of results at the International Society for Heart and Lung Transplantation meeting in Toronto in April.
- UPMC Physician Resources for the description of multidisciplinary prehabilitation for heart and lung transplant candidates, its origins as an outpatient-oriented program, and the role of frailty and psychological distress in transplant candidacy.
- NYU Langone Health for the estimate of roughly 3,000 U.S. heart transplants per year and the account of pre-transplant "prehab" exercise and lifestyle modification for debilitated candidates.
- The European clinical consensus statement on prevention and rehabilitation after heart transplantation, via Frontiers/Transplant International, for the framing of prehabilitation phases, the multidisciplinary team, and the persistent limits on long-term survival and quality of life among transplant recipients.
- The AAPM&R PM&R KnowledgeNow chapter on cardiac rehabilitation before and after transplantation for the UNOS allocation system based on wait time, illness severity, and geography, and the rationale for early multidisciplinary rehabilitation.
- The Hospital Clínic trimodal prehabilitation trial materials for the general evidence that pre-surgical physical training, nutritional, and psychological support can reduce complications and speed recovery.